129 related articles for article (PubMed ID: 16060665)
1. Structural basis of compound recognition by adenosine deaminase.
Kinoshita T; Nakanishi I; Terasaka T; Kuno M; Seki N; Warizaya M; Matsumura H; Inoue T; Takano K; Adachi H; Mori Y; Fujii T
Biochemistry; 2005 Aug; 44(31):10562-9. PubMed ID: 16060665
[TBL] [Abstract][Full Text] [Related]
2. Conformational change of adenosine deaminase during ligand-exchange in a crystal.
Kinoshita T; Tada T; Nakanishi I
Biochem Biophys Res Commun; 2008 Aug; 373(1):53-7. PubMed ID: 18549808
[TBL] [Abstract][Full Text] [Related]
3. Domain motions and the open-to-closed conformational transition of an enzyme: a normal mode analysis of S-adenosyl-L-homocysteine hydrolase.
Wang M; Borchardt RT; Schowen RL; Kuczera K
Biochemistry; 2005 May; 44(19):7228-39. PubMed ID: 15882061
[TBL] [Abstract][Full Text] [Related]
4. Effect of a chemical modification on the hydrated adenosine intermediate produced by adenosine deaminase and a model reaction for a potential mechanism of action of 5-aminoimidazole ribonucleotide carboxylase.
Groziak MP; Huan ZW; Ding H; Meng Z; Stevens WC; Robinson PD
J Med Chem; 1997 Oct; 40(21):3336-45. PubMed ID: 9341908
[TBL] [Abstract][Full Text] [Related]
5. The structure of Escherichia coli cytosine deaminase.
Ireton GC; McDermott G; Black ME; Stoddard BL
J Mol Biol; 2002 Jan; 315(4):687-97. PubMed ID: 11812140
[TBL] [Abstract][Full Text] [Related]
6. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
7. A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization.
Terasaka T; Kinoshita T; Kuno M; Nakanishi I
J Am Chem Soc; 2004 Jan; 126(1):34-5. PubMed ID: 14709046
[TBL] [Abstract][Full Text] [Related]
8. Structural and kinetic characterization of Escherichia coli TadA, the wobble-specific tRNA deaminase.
Kim J; Malashkevich V; Roday S; Lisbin M; Schramm VL; Almo SC
Biochemistry; 2006 May; 45(20):6407-16. PubMed ID: 16700551
[TBL] [Abstract][Full Text] [Related]
9. Complexes of adenosine deaminase with two potent inhibitors: X-ray structures in four independent molecules at pH of maximum activity.
Wang Z; Quiocho FA
Biochemistry; 1998 Jun; 37(23):8314-24. PubMed ID: 9622483
[TBL] [Abstract][Full Text] [Related]
10. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
[TBL] [Abstract][Full Text] [Related]
11. Non-linear quantitative structure-activity relationship for adenine derivatives as competitive inhibitors of adenosine deaminase.
Sadat Hayatshahi SH; Abdolmaleki P; Safarian S; Khajeh K
Biochem Biophys Res Commun; 2005 Dec; 338(2):1137-42. PubMed ID: 16256072
[TBL] [Abstract][Full Text] [Related]
12. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site.
Rummey C; Metz G
Proteins; 2007 Jan; 66(1):160-71. PubMed ID: 17068815
[TBL] [Abstract][Full Text] [Related]
13. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.
Terasaka T; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Inoue T; Tanaka K; Nakamura K
J Med Chem; 2005 Jul; 48(15):4750-3. PubMed ID: 16033254
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors.
Terasaka T; Kinoshita T; Kuno M; Seki N; Tanaka K; Nakanishi I
J Med Chem; 2004 Jul; 47(15):3730-43. PubMed ID: 15239652
[TBL] [Abstract][Full Text] [Related]
15. Theoretical study of inhibition of adenosine deaminase by (8R)-coformycin and (8R)-deoxycoformycin.
Marrone TJ; Straatsma TP; Briggs JM; Wilson DK; Quiocho FA; McCammon JA
J Med Chem; 1996 Jan; 39(1):277-84. PubMed ID: 8568817
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing between bioactive and modeled compound conformations through mining of emerging chemical patterns.
Auer J; Bajorath J
J Chem Inf Model; 2008 Sep; 48(9):1747-53. PubMed ID: 18698838
[TBL] [Abstract][Full Text] [Related]
17. Understanding the structural basis for substrate and inhibitor recognition in eukaryotic GH11 xylanases.
Vardakou M; Dumon C; Murray JW; Christakopoulos P; Weiner DP; Juge N; Lewis RJ; Gilbert HJ; Flint JE
J Mol Biol; 2008 Feb; 375(5):1293-305. PubMed ID: 18078955
[TBL] [Abstract][Full Text] [Related]
18. Probing inhibition mechanisms of adenosine deaminase by using molecular dynamics simulations.
Tian X; Liu Y; Zhu J; Yu Z; Han J; Wang Y; Han W
PLoS One; 2018; 13(11):e0207234. PubMed ID: 30444912
[TBL] [Abstract][Full Text] [Related]
19. Structures of dimeric nonstandard nucleotide triphosphate pyrophosphatase from Pyrococcus horikoshii OT3: functional significance of interprotomer conformational changes.
Lokanath NK; Pampa KJ; Takio K; Kunishima N
J Mol Biol; 2008 Jan; 375(4):1013-25. PubMed ID: 18062990
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and structural studies of A-to-I editing by tRNA:A34 deaminases at the wobble position of transfer RNA.
Elias Y; Huang RH
Biochemistry; 2005 Sep; 44(36):12057-65. PubMed ID: 16142903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
